ChronoScale Corporation Common Stock (NASDAQ:CHRN) Short Interest Update

Key Points

• Short interest fell 49.4% to 598,565 shares as of July 31, down from 1.18 million shares two weeks earlier. Short interest represents 18.0% of shares outstanding, with a days-to-cover ratio of 2.1.
• CHRN traded at $20.93, within a wide 12-month range of $3.01 to $30.00, while reporting a quarterly loss of $3.89 per share on $18.09 million in revenue. Analysts expect a full-year loss of $0.10 per share.
• Several hedge funds initiated positions during the second quarter, but institutional ownership remains relatively low at 6.42% of outstanding shares.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 598,565 shares, a decrease of 49.4% from the July 15th total of 1,182,882 shares. Based on an average daily volume of 281,263 shares, the days-to-cover ratio is presently 2.1 days. Currently, 18.0% of the shares of the company are sold short.

ChronoScale Corporation Common Stock Stock Performance

CHRN traded up $0.31 during midday trading on Friday, reaching $20.93. The company's stock had a trading volume of 99,789 shares, compared to its average volume of 213,151. The company has a current ratio of 1.55, a quick ratio of 1.03 and a debt-to-equity ratio of 0.25. The company has a fifty day simple moving average of $21.40 and a 200 day simple moving average of $15.22. The stock has a market cap of $74.51 million, a P/E ratio of -3.89 and a beta of 1.00. ChronoScale Corporation Common Stock has a twelve month low of $3.01 and a twelve month high of $30.00.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($3.89) EPS for the quarter. ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%.The business had revenue of $18.09 million for the quarter. Research analysts expect that ChronoScale Corporation Common Stock will post -0.1 earnings per share for the current year.

Institutional Trading of ChronoScale Corporation Common Stock

Hedge funds have recently bought and sold shares of the stock. Osbon Capital Management LLC bought a new position in shares of ChronoScale Corporation Common Stock during the 2nd quarter worth about $81,000. TrinityBridge Ltd acquired a new position in shares of ChronoScale Corporation Common Stock during the second quarter valued at about $737,000. Great Lakes Advisors LLC bought a new stake in shares of ChronoScale Corporation Common Stock in the second quarter valued at about $755,000. J.Safra Asset Management Corp bought a new stake in shares of ChronoScale Corporation Common Stock in the second quarter valued at about $48,000. Finally, Roble Belko & Company Inc grew its position in ChronoScale Corporation Common Stock by 104.5% during the first quarter. Roble Belko & Company Inc now owns 2,338 shares of the company's stock worth $25,000 after buying an additional 1,195 shares in the last quarter. 6.42% of the stock is owned by institutional investors.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc NASDAQ: EKSO is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source